Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33341
Title: Diffuse large B-cell lymphoma.
Austin Authors: Barraclough, Allison ;Hawkes, Eliza A ;Sehn, Laurie H;Smith, Sonali M
Affiliation: Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Olivia Newton-John Cancer Wellness and Research Centre
BC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, British Columbia, Canada.
The University of Chicago Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA.
University of Melbourne, Medical School, Melbourne, Victoria, Australia.
Monash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.
Issue Date: 12-Jul-2023
Date: 2023
Publication information: Hematological Oncology 2023-07-12
Abstract: Large B-cell lymphoma, the prototype of aggressive non-Hodgkin lymphomas, is both the most common lymphoma and accounts for the highest global burden of lymphoma-related deaths. For nearly 4 decades, the goal of treatment has been "cure", first based on CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and subsequently with rituximab plus CHOP. However, there is significant clinical, pathologic, and biologic heterogeneity, and not all patients are cured. Understanding and incorporating this biologic heterogeneity into treatment decisions unfortunately is not yet standard of care. Despite this gap, we now have significant advances in frontline, relapsed, and refractory settings. The POLARIX trial shows, for the first time, improved progression-free survival in a prospective randomized phase 3 setting. In the relapsed and refractory settings, there are now many approved agents/regimens, and several bispecific antibodies poised to join the arsenal of options. While chimeric antigen receptor T-cell therapy is discussed in detail elsewhere, it has quickly become an excellent option in the second-line setting and beyond. Unfortunately, special populations such as older adults continue to have poor outcomes and be underrepresented in trials, although a new generation of trials aim to address this disparity. This brief review will highlight the key issues and advances that offer improved outcomes to an increasing portion of patients.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33341
DOI: 10.1002/hon.3202
ORCID: 0000-0002-9893-4949
Journal: Hematological Oncology
PubMed URL: 37435781
ISSN: 1099-1069
Type: Journal Article
Subjects: antibody-drug conjugates
diffuse large B-cell lymphoma
older adults
treatment
Appears in Collections:Journal articles

Show full item record

Page view(s)

32
checked on Dec 2, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.